AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Short Interest Down 14.8% in December

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO – Get Rating) was the recipient of a significant decrease in short interest in the month of December. As of December 30th, there was short interest totalling 816,800 shares, a decrease of 14.8% from the December 15th total of 958,500 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 0.7 days.

Institutional Investors Weigh In On AVEO Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SNC bought a new stake in shares of AVEO Pharmaceuticals in the 3rd quarter valued at approximately $49,000. PDT Partners LLC bought a new stake in shares of AVEO Pharmaceuticals in the 1st quarter valued at approximately $61,000. Barclays PLC lifted its stake in shares of AVEO Pharmaceuticals by 35.4% in the 3rd quarter. Barclays PLC now owns 7,822 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 2,044 shares during the last quarter. Dakota Wealth Management bought a new stake in shares of AVEO Pharmaceuticals in the 1st quarter valued at approximately $70,000. Finally, Cookson Peirce & Co. Inc. bought a new stake in shares of AVEO Pharmaceuticals in the 3rd quarter valued at approximately $99,000. 49.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AVEO has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered AVEO Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price objective for the company. in a research note on Tuesday, November 8th. SVB Leerink lowered AVEO Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, October 24th. Robert W. Baird lowered AVEO Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, October 18th. HC Wainwright lowered AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 18th. Finally, Jonestrading lowered AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 31st. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $15.00.

AVEO Pharmaceuticals Price Performance

Shares of AVEO Pharmaceuticals stock opened at $15.00 on Friday. The stock has a 50 day moving average of $14.92 and a 200 day moving average of $11.25. AVEO Pharmaceuticals has a 12 month low of $3.06 and a 12 month high of $15.00. The firm has a market cap of $521.45 million, a PE ratio of -17.86 and a beta of 1.00. The company has a current ratio of 2.37, a quick ratio of 2.35 and a debt-to-equity ratio of 0.94.

AVEO Pharmaceuticals (NASDAQ:AVEO – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.07. AVEO Pharmaceuticals had a negative return on equity of 81.66% and a negative net margin of 30.79%. The company had revenue of $30.45 million during the quarter, compared to analyst estimates of $29.95 million. On average, research analysts expect that AVEO Pharmaceuticals will post -0.68 EPS for the current fiscal year.

AVEO Pharmaceuticals Company Profile

(Get Rating)

AVEO Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E.